Next Article in Journal
Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?
Previous Article in Journal
Carbon-Based Nanomaterials
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)

by
Magdalena Markowicz-Piasecka
1,
Johanna Huttunen
2,
Ahmed Montaser
2,
Santosh Kumar Adla
2,3,
Seppo Auriola
2,
Marko Lehtonen
2 and
Kristiina M. Huttunen
2,*
1
Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151 Lodz, Poland
2
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
3
Institute of Organic Chemistry and Biochemistry (IOCB), Czech Academy of Sciences, Flemingovo Namesti 542/2, 160 00 Prague, Czech Republic
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(14), 7727; https://doi.org/10.3390/ijms22147727
Submission received: 1 July 2021 / Revised: 13 July 2021 / Accepted: 17 July 2021 / Published: 20 July 2021
(This article belongs to the Section Molecular Pharmacology)

Abstract

Efflux transporters, namely ATP-binding cassette (ABC), are one of the primary reasons for cancer chemoresistance and the clinical failure of chemotherapy. Ganciclovir (GCV) is an antiviral agent used in herpes simplex virus thymidine kinase (HSV-TK) gene therapy. In this therapy, HSV-TK gene is delivered together with GCV into cancer cells to activate the phosphorylation process of GCV to active GCV-triphosphate, a DNA polymerase inhibitor. However, GCV interacts with efflux transporters that are responsible for the resistance of HSV-TK/GCV therapy. In the present study, it was explored whether GCV and its more lipophilic derivative (1) could inhibit effluxing of another chemotherapeutic, methotrexate (MTX), out of the human breast cancer cells. Firstly, it was found that the combination of GCV and MTX was more hemocompatible than the corresponding combination with compound 1. Secondly, both GCV and compound 1 enhanced the cellular accumulation of MTX in MCF-7 cells, the MTX exposure being 13–21 times greater compared to the MTX uptake alone. Subsequently, this also reduced the number of viable cells (41–56%) and increased the number of late apoptotic cells (46–55%). Moreover, both GCV and compound 1 were found to interact with breast cancer resistant protein (BCRP) more effectively than multidrug-resistant proteins (MRPs) in these cells. Since the expression of BCRP was higher in MCF-7 cells than in MDA-MB-231 cells, and the cellular uptake of GCV and compound 1 was smaller but increased in the presence of BCRP-selective inhibitor (Fumitremorgin C) in MCF-7 cells, we concluded that the improved apoptotic effects of higher MTX exposure were raised mainly from the inhibition of BCRP-mediated efflux of MTX. However, the effects of GCV and its derivatives on MTX metabolism and the quantitative expression of MTX metabolizing enzymes in various cancer cells need to be studied more thoroughly in the future.
Keywords: breast cancer resistant protein (BCRP); ganciclovir (GCV); methotrexate (MTX); MCF-7/MDA-MB-231 human breast cancer cells; multidrug resistance (MDR) breast cancer resistant protein (BCRP); ganciclovir (GCV); methotrexate (MTX); MCF-7/MDA-MB-231 human breast cancer cells; multidrug resistance (MDR)

Share and Cite

MDPI and ACS Style

Markowicz-Piasecka, M.; Huttunen, J.; Montaser, A.; Adla, S.K.; Auriola, S.; Lehtonen, M.; Huttunen, K.M. Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP). Int. J. Mol. Sci. 2021, 22, 7727. https://doi.org/10.3390/ijms22147727

AMA Style

Markowicz-Piasecka M, Huttunen J, Montaser A, Adla SK, Auriola S, Lehtonen M, Huttunen KM. Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP). International Journal of Molecular Sciences. 2021; 22(14):7727. https://doi.org/10.3390/ijms22147727

Chicago/Turabian Style

Markowicz-Piasecka, Magdalena, Johanna Huttunen, Ahmed Montaser, Santosh Kumar Adla, Seppo Auriola, Marko Lehtonen, and Kristiina M. Huttunen. 2021. "Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP)" International Journal of Molecular Sciences 22, no. 14: 7727. https://doi.org/10.3390/ijms22147727

APA Style

Markowicz-Piasecka, M., Huttunen, J., Montaser, A., Adla, S. K., Auriola, S., Lehtonen, M., & Huttunen, K. M. (2021). Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP). International Journal of Molecular Sciences, 22(14), 7727. https://doi.org/10.3390/ijms22147727

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop